Table 3. . Univariate analysis and multivariate analysis of factors associated with progression-free survival in patients after progression-free survival.
| mPFS, month (95% CI) | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR (95%CI) | p-value | HR (95%CI) | p-value | ||
| Sex Male Female |
10.8(9.3–12.3) 8.8(6.2–11.5) |
0.987 (0.684–1.424) |
0.945 |
1.142 (0.673–1.937) |
0.622 |
| Age <65 years ≥65 years |
11.0 (9.3–12.7) 9.5 (6.6–12.3) |
1.003 (0.710–1.418) |
0.987 |
0.984 (0.691–1.401) |
0.929 |
| ECOG 0 1 |
10.6 (9.1–12.1) 8.9 (3.1–14.7) |
1.085 (0.752–1.565) |
0.664 |
0.954 (0.649–1.403) |
0.812 |
| Smoking status Never Current/former |
9.2 (7.1–11.3) 11.1 (9.1–13.1) |
0.932 (0.663–1.309) |
0.684 |
1.113 (0.685–1.808) |
0.664 |
| Brain metastases No Yes |
11.0 (9.2–12.8) 7.3 (5.0–9.6) |
2.063 (1.289–3.301) |
0.003 |
2.448 (1.463–4.096) |
0.001 |
| Liver metastases No Yes |
11.1 (9.5–12.7) 6.8 (5.9–7.7) |
1.821 (1.091–3.038) |
0.022 |
1.963 (1.155–3.336) |
0.013 |
| Bone metastases No Yes |
11.4 (9.3–13.6) 7.1 (4.8–9.4) |
1.542 (1.096–2.169) |
0.013 |
1.688 (1.137–2.507) |
0.009 |
| Stage IIIB/IIIC IV |
11.1 (7.3–15.0) 9.7 (7.9–11.4) |
1.027 (0.591–1.785) |
0.926 |
0.695 (0.380–1.273) |
0.239 |
| Treatment regimens BC IC |
8.2 (6.3–10.1) 13.5 (10.9–16.1) |
0.637 (0.456–0.889) |
0.008 |
0.674 (0.479–0.947) |
0.023 |
HR: Hazard Ratio; PFS: Progression-free survival.